{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:19:19Z","timestamp":1790626759073,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/igc.0b013e3182681cfd","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T23:57:26Z","timestamp":1351036646000},"page":"1474-1482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients"],"prefix":"10.1016","volume":"22","author":[{"given":"Karina Dahl","family":"Steffensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Waldstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Brandslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182681cfd_bb0005","first-page":"5007","article-title":"Identification by cDNA microarray of genes involved in ovarian carcinogenesis","volume":"60","author":"Ono","year":"2000","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0010","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1073\/pnas.98.3.1176","article-title":"Analysis of gene expression prof iles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer","volume":"98","author":"Welsh","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0015","first-page":"5895","article-title":"Genetic analysis of early- versus late-stage ovarian tumors","volume":"61","author":"Shridhar","year":"2001","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0030","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","article-title":"Proteins with whey-acidic-protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0040","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0050","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1158\/1055-9965.EPI-08-1034","article-title":"Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125","volume":"18","author":"Shah","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0055","first-page":"111","article-title":"HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses","volume":"11","author":"Abdel-Azeez","year":"2010","journal-title":"Asian PacJ Cancer Prev."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0060","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin Chem Lab Med."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0080","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1515\/CCLM.2011.709","article-title":"The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses","volume":"49","author":"Lenhard","year":"2011","journal-title":"Clin Chem Lab Med."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0100","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","article-title":"Serum human epididymis protein 4 (HE4) and risk for ovarian malignancy algorithm (ROMA) as new diagnostic and prognostic tools for epithelial ovarian cancer management","volume":"20","author":"Bandiera","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0105","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumour Biol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0110","first-page":"1701","article-title":"Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer","volume":"19","author":"Kong","year":"2011","journal-title":"Ann Surg Oncol."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm","volume":"104","author":"van Gorp","year":"2011","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/IGC.0b013e3181a12e09","article-title":"The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer","volume":"19","author":"Steffensen","year":"2009","journal-title":"IntJ Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e3182681cfd_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24057992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24057992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:29:17Z","timestamp":1753223357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24057992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1048891X24057992"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182681cfd","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182681cfd","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}